Managing A Case of Heavily Pretreated Recurrent Ovarian Cancer

Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study.

Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.